Home » Newsletters » BioWorld Science

BioWorld Science

April 9, 2021

View Archived Issues

Breaks are good for T-cell productivity, too

Premetastatic niche is prepared via leaky gut in colorectal cancer

Patient dosing starts in first-in-human study of DS-1594 as treatment of AML and ALL

IND application for JS-007 injection receives acceptance notice in Japan

Enrollment ongoing in phase II/III study of pyronaridine/artesunate for the treatment of COVID-19

Phase III COV-BARRIER study of baricitinib in COVID-19 does not meet primary endpoint

Phase II study of zanubrutinib in COVID-19 misses coprimary efficacy endpoints

Naphthalene monoimide TGR-63 for treating Alzheimer's disease

Allosteric MALT1 inhibitors from Toray Industries for the treatment of psoriasis

Bristol Myers Squibb reports positive topline data from phase III CheckMate-648 trial

FDA places partial clinical hold on first-in-human study of RVU-120

Indian researchers patent ENPP1 inhibitors

Novartis presents new KMT2A inhibitors

Vicore Pharma discloses AGTR2 agonists

Preliminary data from phase Ib trial of gedatolisib plus palbociclib and endocrine therapy

Roche synthesizes new TLR antagonists

VSIG4-targeting antibodies presented by Y-Biologics and Pierre Fabre Medicament

Phase II study of MIB-626 enrolling adults with Friedreich's ataxia

Dosing begins in phase I/II substudy of pembrolizumab in melanoma brain metastasis

Spinal cord stimulation reduces diabetic neuropathy pain

Enrollment begins in phase II study of ATR-002 in hospitalized patients with COVID-19

Bristol Myers Squibb starts enrolling patients in phase I study of BMS-986158 in myelofibrosis

Positive 12-month data presented from phase II TOPAZ study of apitegromab in SMA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...